Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
Data Policies
REVIEW
Questions and Answers About the use of omalizumab in clinical practice
| 1 | Director of Pulmonary Department, 424 General Army Hospital, Thessaloniki, Greece |
| 2 | Director of NHS, Pulmonary Department, G. Papanikolaou General Hospital, Thessaloniki, Greece, National Delegate of ERS |
CORRESPONDING AUTHOR
Pneumon 2017;30(2):92–96
CONFLICTS OF INTEREST
Both authors have participated as speakers in Satellite
Symposiums and in Advisory Boards organized by Novartis.
FUNDING
None
REFERENCES (36)
2.
Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101:1483-92.
3.
Hamilton RG. Accuracy of US Food and Drug Administration – cleared IgE antibody assays in the presence of anti-IgE (omalizumab). JACI 2006; 117:759.
4.
Cox L, Platts-Mills TA, Finegold I; American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120:1373-7.
5.
Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009; 64:1728-36.
7.
Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-97.
8.
Limb SL, Starke PR, Lee CE, Chowdhury BA. elayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007;120:1378-81.
9.
Hanania NA, Wenzel S, Rosén K, et al. Exploring the Effects of Omalizumab in Allergic Asthma. An Analysis of Biomarkers in the EXTRA Study. Am J Respir Crit Care Med 2013; 187:804-11.
10.
Kallieri M, Papioannou AI, Papathanasiou E, et al. Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study. Postgrad Med 2017;28:1-7. doi:10.1080/00325481.2017.1321945. [Epub ahead of print].
11.
MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Downregulation of Fc (epsilon) R expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438.
12.
Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumabinduced reductions in mast cell Fcepsilon RI expression and function. JACI 2004;114:527.
13.
Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66:671-8.
14.
Humbert M, Boulet LP, Niven RM, et al. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009;64:81-4.
15.
Pauwels B, Jonstam K, Bachert C. Emerging biologics for the treatment of chronic rhinosinusitis. Expert Rev Clin Immunol 2015;11:349-61.
16.
Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013;131:110-6.
17.
Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383-9.
18.
Stokes JR, Casale TB. The Use of Anti-IgE Therapy Beyond Allergic Asthma. J Allergy Clin Immunol Pract 2015;3:162-6.
19.
Omalizumab + Infliximab; Omalizumab + adalimumab, omalizumab + etanercept; Omalizumab + golimumab; Omalizumab + certolizumab pegol. Stockley’s Drug Interactions. Medicines Complete. Available at: http://www.medicinescomplete.c....
20.
Drugdex®, Micromedex®. Truven Health Analytics. Available at: www.micromedexsolutions.com (accessed 5th June 2014).
21.
Puéchal X, Rivereau P, Vichon F. Churg–Strauss syndrome associated with omalizumab. Eur J Intern Med 2008;19:364-6.
22.
Wechsler ME, Wong DA, Miller MK, et al. Churg-Strauss Syndrome in Patients Treated With Omalizumab. Chest 2009; 136:507-18.
23.
Giavina-Bianchi P, Kalil J. Omalizumab administration in ChurgStrauss syndrome. Eur J Intern Med 2009;20:e139.
24.
Kong JS, Teuber SS, Gershwin ME. Potential adverse events with biologic response modifiers. Autoimmun Rev 2006;5:471-85.
25.
Kupryś-Lipińska I, Tworek D, Kuna P. Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies. Postepy Dermatol Alergol 2014;31:104-7.
26.
Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol 2015;135:407-12.
27.
Molimard M, Mala L, Bourdeix I, Le Gros V. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med 2014;108:571-6.
28.
Tzortzaki EG, Georgiou A, Kampas D, et al. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean «real-life» experience. Pulm Pharmacol Ther 2012; 25:77-82.
29.
Nopp A, Johansson SG, Adédoyin J, et al. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010; 65:56-60.
30.
Pace E, Ferraro M, Bruno A, et al. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma 2011;48:387-92.
31.
Papadopoulos NG, Arakawa H, Carlsen KH, et al; International consensus on (ICON) pediatric asthma. Allergy 2012;67:976-97.
32.
Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014;134:560-7.
33.
Lafeuille MH, Gravel J, Zhang J, et al. Association between consistent omalizumab treatment and asthma control. J Allergy Clin Immunol Pract 2013;1:51-7.
34.
Roth M, Zhong J, Zumkeller C, et al. The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodeling. Plos One 2013;8:56015.
35.
Roth M, Zhao F, Zhong J, et al. Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab. Plos One 2015;10:e0136549.
36.
Mauri P, Riccio AM, Rossi R, et al. Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunology Letters 2014;162:2–10.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.